Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Dapagliflozin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC5A2 known ✓ | P31639 | 20/20 | 1.00 |
| ▸ | SLC5A1 | P13866 | 14/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 1/20 | 1.00 |
| ▸ | SLC5A11 | Q8WWX8 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dapagliflozin SCHEMBL14949160 | 1.00 | SLC5A2 (1.00) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| Dapagliflozin SCHEMBL16155111 | 1.00 | SLC5A2 (1.00) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| Dapagliflozin SCHEMBL12781978 | 1.00 | SLC5A2 (1.00) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| Dapagliflozin SCHEMBL16001389 | 1.00 | SLC5A2 (1.00) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| Dapagliflozin SCHEMBL15906654 | 1.00 | SLC5A2 (1.00) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| Dapagliflozin SCHEMBL14149845 | 1.00 | SLC5A2 (1.00) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| Dapagliflozin SCHEMBL23542057 | 1.00 | SLC5A2 (1.00) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| Dapagliflozin SCHEMBL499725 | 1.00 | SLC5A2 (1.00) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| Dapagliflozin SCHEMBL15281296 | 1.00 | SLC5A2 (1.00) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| Dapagliflozin SCHEMBL18214900 | 1.00 | SLC5A2 (1.00) | SLC5A2SLC5A1ADRA2ASLC5A11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2018029611-A1 | NOVEL PROCESSES FOR PREPARATION OF DAPAGLIFLOZIN OR ITS SOLVATES OR CO-CRYSTALS THEREOF | LAURUS LABS LIMITED (IN) | 2018-02-15 | — | — | WO | disclosed |